Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm Group™ Presents The ‘JCA Mauvernay Award 2013’

Published: Tuesday, October 08, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
Doctors Kitabayashi and Yano will receive awards during the General Assembly of the 72nd Annual Conference of the JCA in Yokohama.

Debiopharm Group™ (Debiopharm) will be presenting the ‘JCA-Mauvernay Award’ on October 5, to Doctors Issay Kitabayashi from Tokyo National Cancer Center Research Institute for his basic research on ‘Molecular study of acute myeloid leukemia and its application for therapy’ and Seiji Yano from Kanazawa University for his applied research on ‘Circumvention of molecular targeted drug resistance in lung cancer’.

Doctors Kitabayashi and Yano will receive their Awards during the General Assembly of the 72nd Annual Conference of the Japanese Cancer Association (JCA) in Yokohama on the following theme: ‘Cancer research providing hope to fight against cancer’.

Dr. Tetsuo Noda, President of the JCA and a Debiopharm Group representative will present the trophies to both scientists.

“The selecting committee members chose the nominees for the high standard and application possibilities of their research. Debiopharm is honored to be part of this Award with the JCA and wishes both scientists success with their work,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Dr Kitabayashi focuses on the molecular study of the basis of the development of acute myeloid leukemia (AML). He shows that it is related to chromosomal rearrangements modifying the function of genes involved in transcription and hematopoiesis (AML1, PML, MOZ).

Molecular drugs like EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (TKIs) show dramatic effects in lung cancer patients. However resistance to EGFR-TKIs is a major problem in current clinical practice.

Dr Yano aims to conduct clinical trials to elucidate and overcome the molecular mechanisms involved in the resistance to lung cancer drugs and to establish treatments to overcome it.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncotest and Debiopharm Announce a Successful Partnership
Successful completion of first biomarker projects at Oncotest.
Wednesday, April 24, 2013
Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor
Study to test Debio 0932 in patients with advanced non-small cell lung cancer.
Friday, August 17, 2012
Debiopharm and Vifor Pharma Sign an Exclusive Agreement
Distribution and commercialization of Pamorelin® LA in Switzerland.
Monday, May 21, 2012
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!